Editas Medicine investors back directors and auditor

Editas Medicine held its 2026 annual stockholder meeting, where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting.

Rhea-AI Filing Summary

Editas Medicine held its 2026 annual stockholder meeting, where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Connaughton received 28,660,181 votes for and 10,789,549 withheld, while Levy received 37,095,058 votes for and 2,354,672 withheld, in each case with 26,404,190 broker non-votes.

Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 32,914,258 votes for, 6,322,885 against, 212,587 abstentions, and 26,404,190 broker non-votes. In addition, they ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 64,686,839 votes for, 774,471 against, and 392,610 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Bernadette Connaughton: 28,660,181 votes Votes for Elliott Levy, M.D.: 37,095,058 votes Say-on-pay votes for: 32,914,258 votes +3 more

6 metrics

Votes for Bernadette Connaughton 28,660,181 votes Election as Class I director at 2026 annual meeting

Votes for Elliott Levy, M.D. 37,095,058 votes Election as Class I director at 2026 annual meeting

Say-on-pay votes for 32,914,258 votes Advisory approval of named executive officer compensation

Say-on-pay votes against 6,322,885 votes Advisory vote on executive compensation

Auditor ratification votes for 64,686,839 votes Ratification of PricewaterhouseCoopers LLP for fiscal year ending December 31, 2026

Auditor ratification votes against 774,471 votes Ratification of PricewaterhouseCoopers LLP

Key Terms

Annual Meeting of Stockholders, Class I directors, non-binding, advisory vote, independent registered public accounting firm, +1 more

5 terms

Annual Meeting of Stockholders regulatory

"held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)."

Class I directors regulatory

"elected Bernadette Connaughton and Elliott Levy, M.D., to serve as Class I directors"

Class I directors are the subset of a company’s board whose terms expire at a specific annual meeting under a staggered election system that divides directors into multiple groups with different re-election years. For investors this matters because staggered classes slow how quickly shareholders can replace the board, affecting takeover risk, governance change and the pace of corporate decisions — like rotating only part of a team instead of swapping everyone at once.

non-binding, advisory vote regulatory

"approved, on an advisory basis, the compensation paid to its named executive officers."

independent registered public accounting firm regulatory

"ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Broker Non-Votes financial

"The results of the stockholders’ vote with respect to the election of such Class I directors were as follows"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Editas Medicine (EDIT) stockholders decide at the 2026 annual meeting?

Stockholders elected two Class I directors, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor for 2026. These routine governance decisions confirm board composition, support the pay program, and maintain continuity with the current independent audit firm.

Who was elected to the Editas Medicine (EDIT) board in 2026 and for how long?

Bernadette Connaughton and Elliott Levy, M.D., were elected as Class I directors to serve until the 2029 annual meeting. Their terms continue until that meeting and until their successors are duly elected and qualified, maintaining board oversight and continuity for the company.

How did Editas Medicine (EDIT) stockholders vote on executive compensation in 2026?

Stockholders approved the non-binding advisory vote on named executive officer compensation with 32,914,258 votes for, 6,322,885 against, and 212,587 abstaining. There were 26,404,190 broker non-votes. This indicates overall stockholder support for the company’s existing executive pay structure.

Which audit firm did Editas Medicine (EDIT) stockholders ratify for fiscal year 2026?

Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 64,686,839 votes for, 774,471 against, and 392,610 abstentions, confirming continued engagement of the same external auditor.

What were the vote totals for Editas Medicine (EDIT) director Elliott Levy, M.D.?

Elliott Levy, M.D., received 37,095,058 votes for and 2,354,672 votes withheld, along with 26,404,190 broker non-votes. These results confirm his election as a Class I director, with a term running until the 2029 annual meeting of stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:28 PM Learn about SEC filing dates

0001650664FALSE00016506642026-06-172026-06-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________________________________

FORM 8-K

_________________________________________________________________________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

_________________________________________________________________________________________

Editas Medicine, Inc.

(Exact Name of Registrant as Specified in its Charter)

________________________________________________________________________________________

Delaware			001-37687			46-4097528
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

11 Hurley Street Cambridge, Massachusetts			02141
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code: (617) 401-9000

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.0001 par value per share			EDIT			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 5.07.    Submission of Matters to a Vote of Security Holders

On June 17, 2026, Editas Medicine, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The following is a summary of matters voted on at the 2026 Annual Meeting.

1.The Company’s stockholders elected Bernadette Connaughton and Elliott Levy, M.D., to serve as Class I directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows:

						Votes For						Votes Withheld						Broker Non-Votes
Bernadette Connaughton						28,660,181						10,789,549						26,404,190
Elliott Levy, M.D.						37,095,058						2,354,672						26,404,190

2.The Company’s stockholders approved, on an advisory basis, the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows:

Votes For						Votes Against						Votes Abstaining						Broker Non-Votes
32,914,258						6,322,885						212,587						26,404,190

3.The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes For						Votes Against						Votes Abstaining						Broker Non-Votes
64,686,839						774,471						392,610						0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EDITAS MEDICINE, INC.

Date:

June 18, 2026

By:

/s/ Gilmore O’Neill

Gilmore O’Neill President & Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.8 KB